Hims & Hers Health, Inc. (NYSE:HIMS) Insider Soleil Boughton Sells 2,343 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 2,343 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $29.90, for a total transaction of $70,055.70. Following the completion of the transaction, the insider now directly owns 165,254 shares in the company, valued at $4,941,094.60. This trade represents a 1.40 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Soleil Boughton also recently made the following trade(s):

• On Tuesday, October 29th, Soleil Boughton sold 2,339 shares of Hims & Hers Health stock. The shares were sold at an average price of $23.16, for a total transaction of $54,171.24.
• On Tuesday, October 15th, Soleil Boughton sold 2,339 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.41, for a total transaction of $47,738.99.
• On Tuesday, September 17th, Soleil Boughton sold 2,339 shares of Hims & Hers Health stock. The shares were sold at an average price of $16.50, for a total value of $38,593.50.
• On Tuesday, September 3rd, Soleil Boughton sold 2,345 shares of Hims & Hers Health stock. The stock was sold at an average price of $14.65, for a total value of $34,354.25.

Hims & Hers Health Stock Down 1.1 %

NYSE:HIMS opened at $30.34 on Friday. The company has a market cap of $6.63 billion, a P/E ratio of 68.96 and a beta of 1.06. Hims & Hers Health, Inc. has a twelve month low of $8.09 and a twelve month high of $35.02. The business has a 50 day moving average price of $21.42 and a two-hundred day moving average price of $19.65.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.06 by $0.26. The business had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm’s revenue was up 77.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.04) earnings per share. As a group, analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on HIMS shares. Imperial Capital cut Hims & Hers Health from an “outperform” rating to an “in-line” rating in a report on Friday, August 9th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. Canaccord Genuity Group lifted their price target on shares of Hims & Hers Health from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Bank of America lowered shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and decreased their price target for the company from $32.00 to $18.00 in a report on Thursday, November 14th. Finally, Needham & Company LLC started coverage on Hims & Hers Health in a research note on Thursday, August 22nd. They set a “buy” rating and a $24.00 price objective on the stock. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $20.71.

Institutional Trading of Hims & Hers Health

A number of hedge funds and other institutional investors have recently modified their holdings of HIMS. Vanguard Group Inc. grew its stake in shares of Hims & Hers Health by 1.0% in the first quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock valued at $221,379,000 after buying an additional 136,907 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Hims & Hers Health by 113.1% in the 2nd quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock valued at $121,936,000 after acquiring an additional 3,205,108 shares during the period. State Street Corp raised its holdings in shares of Hims & Hers Health by 4.7% in the 3rd quarter. State Street Corp now owns 4,626,543 shares of the company’s stock valued at $85,221,000 after purchasing an additional 206,078 shares during the period. Geode Capital Management LLC lifted its stake in Hims & Hers Health by 12.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock valued at $79,029,000 after purchasing an additional 482,177 shares during the last quarter. Finally, Wellington Management Group LLP grew its holdings in Hims & Hers Health by 34.5% during the third quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock worth $63,446,000 after purchasing an additional 883,230 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.